Novartis Q1 2026 Results: Strong Growth in Priority Brands Amid Generic Erosion
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Tag: Q1
Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion
Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.
Johnson & Johnson Q1 2026 Results: Financial Growth and Pipeline Breakthroughs
Johnson & Johnson delivers a robust start to the year with the Johnson & Johnson Q1 2026 Results, reporting $24.1 billion in revenue and increasing its full-year earnings guidance amid major clinical approvals.
IQVIA Announces First-Quarter 2025 Financial Results
IQVIA reported $3.829 billion in total revenue for the first quarter that ended on March 31, 2025, a 2.5% increase over the same period in 2024.
Amgen Reports Strong Q1 2025 Results Driven by Robust Volume Growth and Key Product Performance
Amgen Inc. (NASDAQ: AMGN) announced its financial results for the first quarter ended March 31, 2025, showcasing significant revenue growth fueled by strong product volume [Read More…]
Moderna Reports Q1 2025 Results: Revenue Dips, Focus Shifts to Oncology Amid Expense Cuts
Moderna, Inc. announced its financial results for the first quarter ending March 31, 2025, highlighting a strategic realignment towards oncology and other pipeline candidates amidst [Read More…]
Eli Lilly Reported a Very Strong Start to 2025, Characterized by Significant Revenue Growth
Revenue reached $12.73 billion, a substantial 45% increase year-over-year, primarily fueled by strong volume growth from Mounjaro and Zepbound.
